keyword
https://read.qxmd.com/read/38555116/substitution-therapy-for-patients-with-alcohol-dependence-mechanisms-of-action-and-efficacy
#21
JOURNAL ARTICLE
Julien Guiraud, Rainer Spanagel, Wim van den Brink
New approaches for the treatment of alcohol dependence (AD) may improve patient outcomes. Substitution maintenance therapy is one of the most effective treatment options for opioid and nicotine use disorders. So far, there has been little attention to substitution therapy for the treatment of AD. Here, we explain the mechanistic foundations of alcohol substitution maintenance therapy. Alcohol has many primary targets in the brain (and other organs) and the physical interaction of ethanol molecules with these specific ethanol-sensitive sites on a variety of ionotropic receptors (e...
2024: International Review of Neurobiology
https://read.qxmd.com/read/38555115/repurposing-drugs-for-treatment-of-alcohol-use-disorder
#22
REVIEW
Henri-Jean Aubin
Repurposing drugs for the treatment of alcohol dependence involves the use of drugs that were initially developed for other conditions, but have shown promise in reducing alcohol use or preventing relapse. This approach can offer a more cost-effective and time-efficient alternative to developing new drugs from scratch. Currently approved medications for alcohol use disorder (AUD) include acamprosate, disulfiram, naltrexone, nalmefene, baclofen, and sodium oxybate. Acamprosate was developed specifically for AUD, while disulfiram's alcohol-deterrent effects were discovered incidentally...
2024: International Review of Neurobiology
https://read.qxmd.com/read/38545533/nerve-growth-factor-in-psychiatric-disorders-a-scoping-review
#23
REVIEW
Alankrit Jaiswal, Umesh Shreekantiah, Nishant Goyal
BACKGROUND: Neurotrophins have been implicated in multiple psychiatric disorders. Nerve Growth Factor (NGF) is one of the major neurotrophins that has attracted much research interest. Therefore, we undertook, to the best of our knowledge, the first scoping review encompassing all major psychiatric disorders and their relation to NGF. This review aimed to identify the current position of NGF in psychiatric research and to outline present gaps in knowledge, which can be answered with a more detailed systematic review in the future...
November 2023: Indian Journal of Psychological Medicine
https://read.qxmd.com/read/38539681/a-narrative-review-of-current-and-emerging-trends-in-the-treatment-of-alcohol-use-disorder
#24
REVIEW
Muhammet Celik, Mark S Gold, Brian Fuehrlein
Alcohol use disorder (AUD) is a significant contributor to morbidity and mortality in the United States. It contributes to over 140,000 annual deaths, to over 200 related diseases and health conditions globally, and accounts for 5.1% of the global disease burden. Despite its substantial impact, AUD remains undertreated, marked by a scarcity of approved medications. This paper explores the current treatment landscape and novel strategies for both alcohol withdrawal syndrome and AUD. Promising results, including the use of psychedelics alongside psychotherapy, noninvasive neural-circuit-based interventions, phosphodiesterase-4 inhibitors, and GLP-1 receptor agonists, have emerged from recent studies...
March 20, 2024: Brain Sciences
https://read.qxmd.com/read/38537764/pain-in-alcohol-use-disorder-evaluating-effects-of-childhood-trauma-perceived-stress-and-psychological-comorbidity
#25
JOURNAL ARTICLE
M L Schwandt, V A Ramchandani, J Upadhyay, C Ramsden, N Diazgranados, D Goldman
The relationship between pain and alcohol use disorder (AUD) is complex and bidirectional. The current study examines risk factors for pain in a large comprehensively phenotyped sample including individuals from across the spectrum of alcohol use and misuse. Participants (n = 1101) were drawn from the National Institute on Alcohol Abuse and Alcoholism Natural History Protocol and included treatment-seeking AUD inpatients (AUD+Tx, n = 369), individuals with AUD not seeking treatment (AUD+, n = 161), and individuals without AUD (AUD-, n = 571)...
March 25, 2024: Alcohol
https://read.qxmd.com/read/38530674/managing-alcohol-withdrawal-syndrome
#26
REVIEW
Michael Gottlieb, Nicholas Chien, Brit Long
No abstract text is available yet for this article.
March 25, 2024: Annals of Emergency Medicine
https://read.qxmd.com/read/38518662/analysis-of-rising-cases-of-adolescent-opioid-use-presentations-to-the-emergency-department-and-their-management
#27
JOURNAL ARTICLE
Alexander Sidlak, Brent Dibble, Mannet Dhaliwal, Paul Bottone, Ryan Marino, Linda Henry, John Howell
OBJECTIVE: We sought to answer the question of how adolescents (ages 12-17 years old) with opioid-related presentations are currently managed in the ED. The two main outcomes were the proportion of visits where naloxone and buprenorphine were both used and prescribed, and the rate of revisits to the emergency department in the six months following ED presentation. METHODS: This was a multi-center retrospective cross-sectional study. We studied patients presenting to the ED who were 12-17 years old with an opioid-related presentation...
February 29, 2024: Drug and Alcohol Dependence
https://read.qxmd.com/read/38515504/antidepressants-in-people-with-chronic-liver-disease-and-depression-when-are-they-warranted-and-how-to-choose-the-suitable-one
#28
REVIEW
Swapnajeet Sahoo, Eepsita Mishra, Madhumita Premkumar
Most chronic medical illnesses are associated with significant psychiatric comorbidity, especially in the form of depression, anxiety, and suicidality. Chronic liver disease (CLD) is no exception to this and rather is placed uniquely as compared to other diseases because of its intersection with alcohol use disorder and other substance use, which in itself is a mental illness. Patients with CLD may have comorbid psychiatric illnesses; the pharmacokinetic concerns arising out of hepatic dysfunction which affects pharmacotherapy for depression and vice versa...
2024: Journal of Clinical and Experimental Hepatology
https://read.qxmd.com/read/38505174/alcohol-withdrawal-severity-measures-for-identifying-patients-requiring-high-intensity-care
#29
JOURNAL ARTICLE
Daniel C To, Tessa L Steel, Kyle A Carey, Cara J Joyce, Elizabeth M Salisbury-Afshar, Dana P Edelson, Anoop Mayampurath, Matthew M Churpek, Majid Afshar
OBJECTIVES: Alcohol withdrawal syndrome (AWS) may progress to require high-intensity care. Approaches to identify hospitalized patients with AWS who received higher level of care have not been previously examined. This study aimed to examine the utility of Clinical Institute Withdrawal Assessment Alcohol Revised (CIWA-Ar) for alcohol scale scores and medication doses for alcohol withdrawal management in identifying patients who received high-intensity care. DESIGN: A multicenter observational cohort study of hospitalized adults with alcohol withdrawal...
March 2024: Critical care explorations
https://read.qxmd.com/read/38502911/withdrawal-catastrophizing-scale-initial-psychometric-properties-and-implications-for-the-study-of-opioid-use-disorder-and-hyperkatifeia
#30
JOURNAL ARTICLE
Orman Trent Hall, Michael Vilensky, Julie E Teater, Craig Bryan, Kara Rood, Julie Niedermier, Parker Entrup, Stephanie Gorka, Anthony King, David A Williams, K Luan Phan
Background: Discovery of modifiable factors influencing subjective withdrawal experience might advance opioid use disorder (OUD) research and precision treatment. This study explores one factor - withdrawal catastrophizing - a negative cognitive and emotional orientation toward withdrawal characterized by excessive fear, worry or inability to divert attention from withdrawal symptoms. Objectives: We define a novel concept - withdrawal catastrophizing - and present an initial evaluation of the Withdrawal Catastrophizing Scale (WCS)...
March 19, 2024: American Journal of Drug and Alcohol Abuse
https://read.qxmd.com/read/38501811/evaluation-of-clinical-outcomes-associated-with-phenobarbital-with-taper-compared-to-no-taper-for-the-management-of-alcohol-withdrawal-syndrome
#31
JOURNAL ARTICLE
Matthew Thaller, Adrian Wong, Tuyen Yankama, Ifeoma Mary Eche, Pansy Elsamadisi
BACKGROUND: Phenobarbital (PHB) has been shown to be an effective treatment of alcohol withdrawal syndrome (AWS), with multiple dosing strategies used (e.g., single-dose and symptom-triggered). Studies have often used tapered doses, typically following a front-loaded dose, despite PHB's long half-life which should lead to an ability to auto-taper. OBJECTIVE: The purpose of this study was to compare clinical outcomes associated with two PHB dosing strategies (taper [T], no taper [NT]) for AWS...
March 19, 2024: Annals of Pharmacotherapy
https://read.qxmd.com/read/38499081/iuphar-themed-issue-new-strategies-for-medications-to-treat-substance-use-disorders
#32
REVIEW
Surya Pandey, Courtney A Miller
Substance use disorders (SUD) are chronic relapsing disorders governed by continually shifting cycles of positive drug reward experiences and drug withdrawal-induced negative experiences. A large body of research points to plasticity within systems regulating emotional, motivational, and cognitive processes as drivers of continued compulsive pursuit and consumption of substances despite negative consequences. This plasticity is observed at all levels of analysis from molecules to networks, providing multiple avenues for intervention in SUD...
March 16, 2024: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://read.qxmd.com/read/38495426/chronic-alcohol-induced-long-lasting-working-memory-deficits-are-associated-with-altered-histone-h3k9-dimethylation-in-the-prefrontal-cortex
#33
JOURNAL ARTICLE
Mael De Clerck, Martin Manguin, Nadia Henkous, Marion N d'Almeida, Daniel Beracochea, Nicole Mons
INTRODUCTION: Epigenetic modifications have emerged as key contributors to the enduring behavioral, molecular and epigenetic neuroadaptations during withdrawal from chronic alcohol exposure. The present study investigated the long-term consequences of chronic alcohol exposure on spatial working memory (WM) and associated changes of transcriptionally repressive histone H3 lysine 9 dimethylation (H3K9me2 ) in the prefrontal cortex (PFC). METHODS: Male C57BL/6 mice were allowed free access to either 12% (v/v) ethanol for 5 months followed by a 3-week abstinence period or water...
2024: Frontiers in Behavioral Neuroscience
https://read.qxmd.com/read/38485572/a-retrospective-evaluation-of-adjunctive-phenobarbital-vs-benzodiazepine-alone-for-the-treatment-of-moderate-alcohol-withdrawal-in-the-emergency-department
#34
JOURNAL ARTICLE
Jacob A Lebin, Megan E Bass, Kennon Heard, Jason Hoppe, Gabrielle Jacknin
BACKGROUND: Phenobarbital has been used in the emergency department (ED) as both a primary and adjunctive medication for alcohol withdrawal, but previous studies evaluating its impact on patient outcomes are limited by heterogenous symptom severity. OBJECTIVES: We compared the clinical outcomes of ED patients with moderate alcohol withdrawal who received phenobarbital, with or without benzodiazepines, with patients who received benzodiazepine treatment alone. METHODS: This is a retrospective cohort study conducted at a single academic medical center utilizing chart review of ED patients with moderate alcohol withdrawal between 2015 and 2020...
December 14, 2023: Journal of Emergency Medicine
https://read.qxmd.com/read/38479082/cash-outs-during-in-play-sports-betting-who-why-and-what-it-reveals
#35
JOURNAL ARTICLE
E S-L L Sinclair, L Clark, M J A Wohl, M T Keough, H S Kim
Cashing out is a popular feature of modern 'in-play' sports betting that allows sports bettors to withdraw a bet before the sporting event on which the bet was placed is finalized. Previous studies have shown that use of the cash out feature is positively related to problem gambling symptomatology. However, little is known about demographic and psychological characteristics of in-play sports bettors who use the cash out feature, or their motivations for use. To fill this knowledge gap, we recruited 224 adults (18 + years) from Ontario who engaged in in-play sports betting in the past three months...
March 7, 2024: Addictive Behaviors
https://read.qxmd.com/read/38474180/association-between-rmtg-neuropeptide-genes-and-negative-effect-during-alcohol-withdrawal-in-mice
#36
JOURNAL ARTICLE
Yixin Fu, Wenfu Li, Yunlin Mai, Junhao Guan, Ruxuan Ding, Jiawei Hou, Bingqing Chen, Guoxin Cao, Shizhu Sun, Ying Tang, Rao Fu
Alcohol use disorders (AUDs) frequently co-occur with negative mood disorders, such as anxiety and depression, exacerbating relapse through dopaminergic dysfunction. Stress-related neuropeptides play a crucial role in AUD pathophysiology by modulating dopamine (DA) function. The rostromedial tegmental nucleus (RMTg), which inhibits midbrain dopamine neurons and signals aversion, has been shown to increase ethanol consumption and negative emotional states during abstinence. Despite some stress-related neuropeptides acting through the RMTg to affect addiction behaviors, their specific roles in alcohol-induced contexts remain underexplored...
March 2, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38465575/associations-of-adh1b-and-aldh2-genotypes-and-alcohol-flushing-with-drinking-history-withdrawal-symptoms-and-icd-10-criteria-in-japanese-alcohol-dependent-men
#37
JOURNAL ARTICLE
Akira Yokoyama, Tetsuji Yokoyama, Yosuke Yumoto, Tsuyoshi Takimura, Tomomi Toyama, Junichi Yoneda, Kotaro Nishimura, Ruriko Minobe, Takanobu Matsuzaki, Mitsuru Kimura, Sachio Matsushita
OBJECTIVES: Given the high prevalence of fast-metabolizing alcohol dehydrogenase-1B*2 (ADH1B*2) and inactive aldehyde dehydrogenase-2*2 (ALDH2*2) alleles in East Asians, we evaluated how the ADH1B/ALDH2 genotypes and alcohol flushing might affect the development of alcohol dependence (AD). METHODS: We evaluated how the ADH1B/ALDH2 genotypes and self-reported alcohol flushing affected history of drinking events and withdrawal symptoms and ICD-10 criteria in 4116 Japanese AD men...
March 11, 2024: Pharmacogenetics and Genomics
https://read.qxmd.com/read/38464012/network-states-in-the-basolateral-amygdala-predicts-voluntary-alcohol-consumption
#38
Alyssa DiLeo, Pantelis Antonodiou, Katrina Blandino, Eli Conlin, Laverne Melón, Jamie L Maguire
UNLABELLED: Although most adults in the United States will drink alcohol in their life, only about 6% will go on to develop an alcohol use disorder (AUD). While a great deal of work has furthered our understanding of the cycle of addiction, it remains unclear why certain people transition to disordered drinking. Altered activity in regions implicated in AUDs, like the basolateral amygdala (BLA), has been suggested to play a role in the pathophysiology of AUDs, but how these networks contribute to alcohol misuse remains unclear...
March 3, 2024: bioRxiv
https://read.qxmd.com/read/38461744/how-adolescents-lose-control-over-social-networks-a-process-based-approach-to-problematic-social-network-use
#39
JOURNAL ARTICLE
Víctor Ciudad-Fernández, Alfredo Zarco-Alpuente, Tamara Escrivá-Martínez, Rocío Herrero, Rosa Baños
Social networks (SNs) are immensely popular, especially among teenagers, yet our understanding of problematic SNs remains limited. Understanding motivations and patterns of use is crucial given the current prevalence of problematic SNs use. Perarles et al. (2020) distinguish two behavioral control modes: Model-Free Control, where actions are characterized by actions driven by immediate gratification without reflective consideration for long-term consequences, and Model-Based Control, enabling planned and goal-directed actions...
March 7, 2024: Addictive Behaviors
https://read.qxmd.com/read/38461355/ly2444296-a-%C3%AE%C2%BA-opioid-receptor-antagonist-selectively-reduces-alcohol-drinking-in-male-and-female-wistar-rats-with-a-history-of-alcohol-dependence
#40
JOURNAL ARTICLE
Francisco J Flores-Ramirez, Jessica M Illenberger, Glenn Pascasio, Lars Terenius, Rémi Martin-Fardon
Alcohol use disorder (AUD) remains a major public health concern. The dynorphin (DYN)/κ-opioid receptor (KOP) system is involved in actions of alcohol, particularly its withdrawal-associated negative affective states. This study tested the ability of LY2444296, a selective, short-acting, KOP antagonist, to decrease alcohol self-administration in dependent male and female Wistar rats at 8 h abstinence. Animals were trained to orally self-administer 10% alcohol (30 min/day for 21 sessions) and were made dependent via chronic intermittent alcohol vapor exposure for 6 weeks or exposed to air (nondependent)...
March 9, 2024: Scientific Reports
keyword
keyword
11142
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.